Deciphering the Molecular Machinery-Influence of SE-Cadherin on Tumorigenic Traits of Prostate Cancer Cells

Overview

Journal Biology (Basel)

Publisher MDPI

Specialty Biology

Date 2021 Oct 23

PMID 34681106

Authors

Igor Tsaur

Anita Thomas

Eva Juengel

Sebastian Maxeiner

Timothy Grein

Quynh Chi Le

Veronika Muschta

Jochen Rutz

Felix K H Chun

Roman A Blaheta

Affiliations

Soon will be listed here.

Abstract

The serum level of soluble (s)E-cadherin is elevated in several malignancies, including prostate cancer (PCa). This study was designed to investigate the effects of sE-cadherin on the behavior of PCa cells in vitro, with the aim of identifying a potential therapeutic target. Growth as well as adhesive and motile behavior were evaluated in PC3, DU-145, and LNCaP cells. Flow cytometry was used to assess cell cycle phases and the surface expression of CD44 variants as well as α and β integrins. Confocal microscopy was utilized to visualize the distribution of CD44 variants within the cells. Western blot was applied to investigate expression of α3 and β1 integrins as well as cytoskeletal and adhesion proteins. Cell growth was significantly inhibited after exposure to 5 µg/mL sE-cadherin and was accompanied by a G0/G1-phase arrest. Adhesion of cells to collagen and fibronectin was mitigated, while motility was augmented. CD44v4, v5, and v7 expression was elevated while α3 and β1 integrins were attenuated. Blocking integrin α3 reduced cell growth and adhesion to collagen but increased motility. sE-cadherin therefore appears to foster invasive tumor cell behavior, and targeting it might serve as a novel and innovative concept to treat advanced PCa.

References

McFarlane S, McFarlane C, Montgomery N, Hill A, Waugh D . CD44-mediated activation of α5β1-integrin, cortactin and paxillin signaling underpins adhesion of basal-like breast cancer cells to endothelium and fibronectin-enriched matrices. Oncotarget. 2015; 6(34):36762-73. PMC: 4742209. DOI: 10.18632/oncotarget.5461. View

Leung D, Chiu P, Ng C, Teoh J . Novel Strategies for Treating Castration-Resistant Prostate Cancer. Biomedicines. 2021; 9(4). PMC: 8066514. DOI: 10.3390/biomedicines9040339. View

Johnson S, Ramani V, Hennings L, Haun R . Kallikrein 7 enhances pancreatic cancer cell invasion by shedding E-cadherin. Cancer. 2007; 109(9):1811-20. DOI: 10.1002/cncr.22606. View

Virtanen S, Ishizu T, Sandholm J, Loyttyniemi E, Vaananen H, Tuomela J . Alendronate-induced disruption of actin cytoskeleton and inhibition of migration/invasion are associated with cofilin downregulation in PC-3 prostate cancer cells. Oncotarget. 2018; 9(66):32593-32608. PMC: 6135693. DOI: 10.18632/oncotarget.25961. View

Hyder C, Lazaro G, Pylvanainen J, Roberts M, Qvarnstrom S, Eriksson J . Nestin regulates prostate cancer cell invasion by influencing the localisation and functions of FAK and integrins. J Cell Sci. 2014; 127(Pt 10):2161-73. DOI: 10.1242/jcs.125062. View

Grabowska M, Day M . Soluble E-cadherin: more than a symptom of disease. Front Biosci (Landmark Ed). 2011; 17(5):1948-64. PMC: 4183062. DOI: 10.2741/4031. View

Kurozumi A, Goto Y, Matsushita R, Fukumoto I, Kato M, Nishikawa R . Tumor-suppressive microRNA-223 inhibits cancer cell migration and invasion by targeting ITGA3/ITGB1 signaling in prostate cancer. Cancer Sci. 2015; 107(1):84-94. PMC: 4724812. DOI: 10.1111/cas.12842. View

Kwon O, Ryu S, Choi J, Lee S . Roxb. Inhibits Collagen Induced Adhesion and Migration of PC3 and LNCaP Prostate Cancer Cells through the Inhibition of Beta 1 Integrin Expression. Molecules. 2020; 25(13). PMC: 7411785. DOI: 10.3390/molecules25133006. View

Lee Y, Ko D, Yoon J, Lee Y, Kim S . TMEM52B suppression promotes cancer cell survival and invasion through modulating E-cadherin stability and EGFR activity. J Exp Clin Cancer Res. 2021; 40(1):58. PMC: 7919321. DOI: 10.1186/s13046-021-01828-7. View

10.

Xu N, Chen H, Chen S, Xue X, Chen H, Zheng Q . Upregulation of Talin-1 expression associates with advanced pathological features and predicts lymph node metastases and biochemical recurrence of prostate cancer. Medicine (Baltimore). 2016; 95(29):e4326. PMC: 5265801. DOI: 10.1097/MD.0000000000004326. View

11.

Zhu S, Zhao G, Zhao X, Zhan X, Cai M, Geng C . Elevated soluble E-cadherin during the epithelial-mesenchymal transition process and as a diagnostic marker in colorectal cancer. Gene. 2020; 754:144899. DOI: 10.1016/j.gene.2020.144899. View

12.

Kyriakopoulos C, Chen Y, Carducci M, Liu G, Jarrard D, Hahn N . Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol. 2018; 36(11):1080-1087. PMC: 5891129. DOI: 10.1200/JCO.2017.75.3657. View

13.

He Y, Zhang J, Wang S, Huang W, Chen X, He B . [Serum sCD44v6 and sE-cadherin levels in patients with esophageal squamous cell carcinoma]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2012; 41(3):305-9. DOI: 10.3785/j.issn.1008-9292.2012.03.012. View

14.

Uwada J, Mukai S, Terada N, Nakazawa H, Islam M, Nagai T . Pleiotropic effects of probenecid on three-dimensional cultures of prostate cancer cells. Life Sci. 2021; 278:119554. DOI: 10.1016/j.lfs.2021.119554. View

15.

de Wever O, Derycke L, Hendrix A, De Meerleer G, Godeau F, Depypere H . Soluble cadherins as cancer biomarkers. Clin Exp Metastasis. 2007; 24(8):685-97. DOI: 10.1007/s10585-007-9104-8. View

16.

Tsaur I, Thurn K, Juengel E, Gust K, Borgmann H, Mager R . sE-cadherin serves as a diagnostic and predictive parameter in prostate cancer patients. J Exp Clin Cancer Res. 2015; 34:43. PMC: 4490684. DOI: 10.1186/s13046-015-0161-6. View

17.

Singh R, Kapur N, Mir H, Singh N, Lillard Jr J, Singh S . CXCR6-CXCL16 axis promotes prostate cancer by mediating cytoskeleton rearrangement via Ezrin activation and αvβ3 integrin clustering. Oncotarget. 2016; 7(6):7343-53. PMC: 4872790. DOI: 10.18632/oncotarget.6944. View

18.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

19.

Das L, Anderson T, Gard J, Sroka I, Strautman S, Nagle R . Characterization of Laminin Binding Integrin Internalization in Prostate Cancer Cells. J Cell Biochem. 2016; 118(5):1038-1049. PMC: 5553695. DOI: 10.1002/jcb.25673. View

20.

Culp M, Soerjomataram I, Efstathiou J, Bray F, Jemal A . Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates. Eur Urol. 2019; 77(1):38-52. DOI: 10.1016/j.eururo.2019.08.005. View